Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...

Lucid Diagnostics Inc.  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced that Highmark Blue Cross Blue ...

Verde Resources, Inc. announces groundbreaking preliminary findings from the National Center for Asphalt Technology (NCAT), revealing the transformative impact of its TerraZyme® technology in road ...

PR Newswire WASHINGTON, March 13, 2025 American Association of Kidney Patients (AAKP) WASHINGT As the largest and oldest fully independent kidney ...

The DNA polymerase market in the United States is poised for significant expansion, with projections indicating a market size of USD 148.7 million by 2025 and a compound annual growth rate (CAGR) of 5 ...

LONDON - Virax Biolabs Group Limited (NASDAQ:VRAX), a micro-cap biotechnology company with a market value of $6.39 million specializing in immune response detection and viral disease diagnosis, has ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

The Cell-Based Assays Market is projected to grow from $35.3 billion in 2024 to $56.3 billion by 2029, at a 9.8% CAGR, driven by demand for drug disc ...